Ken Kato, ASCO 2023: Highlights in upper gastrointestinal cancers

touchONCOLOGY are joined by editorial board member Dr Ken Kato (National Cancer Centre Hospital, Tokyo, Japan) to discuss a few of his highlights from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer (00:20)

KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer (04:00)

Disclosures: Ken Kato has received grant/research support from: ONO and BMS; he is a member of the advisory Board for ONO, BMS, Chugai, Daiichi Sankyo and AstraZeneca and a speaker’s bureau participant with ONO, BMS and MSD.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of ASCO 2023

Access more content on Gastrointestinal Cancers here